Michael H. Carrel

Michael H. Carrel has served as President and Chief Executive Officer of AtriCure (NASDAQ: ATRC) since November 2012. AtriCure, Inc. is a medical device company that provides innovative solutions for the treatment of atrial fibrillation (Afib) and related conditions. AtriCure’s mission is to reduce the global Afib epidemic and heal the lives of those affected.

Since joining AtriCure, Mr. Carrel has fostered a patient-first company approach by focusing on the three core areas: innovation, clinical science, and education. This strategic approach has led AtriCure to significantly invest in groundbreaking clinical trials for the treatment of Afib, left atrial appendage management and pain management; expand its market presence within Europe and Asia; and grow the global employee base from 200 to over 600 employees. In addition, during Mike’s tenure, AtriCure has acquired two companies, Estech and nContact, adding leading ablation technologies to further AtriCure’s market position worldwide.

His 24-year career includes successful leadership in global organizations in the healthcare and technology industries. Before joining AtriCure, Mr. Carrel was President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company. He led Vital Images to a global leadership position in the healthcare and medical software industry. Under his leadership, the company grew revenue and profitability, increased global market share, expanded its presence to over 90 countries, and lead the company through a sale to Toshiba Medical Systems Corporation. Prior to joining Vital Images, Mike was President and CEO of Zamba Corp., a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug and play broadband wireless access systems.

Mr. Carrel serves on the Board of Medical Device Manufacturers Association (MDMA) and Axonics Modulation Technologies, Inc. He earned a B.S. in Accounting from Pennsylvania State University and an M.B.A. from the Wharton School at the University of Pennsylvania.  Back to top


Mark A. Collar

Mr. Collar has served as one of our directors since February 2008. Mr. Collar retired in 2008 as an officer within the Procter and Gamble Company where his roles included President of the Global Pharmaceuticals and Personal Health business. Mr. Collar joined Procter and Gamble in 1975 as a sales representative, then moved into advertising, and subsequently assumed roles of progressive responsibility within the Health and Personal Care, Beauty Care, New Business Development, Pharmaceuticals and Personal Health Care Products divisions over his 32-year career. Mr. Collar, who now owns his own investment and consulting business, was a director of First Financial Bancorp, a publicly-held bank holding company and Enable Injections, a start-up company focusing on high volume injection devices for biologic drugs and serves in director and advisory roles in several philanthropic, academic and economic development organizations. Mr. Collar received his B.S. from Northern Illinois University. Mr. Collar’s experience as a public company executive and board member provides him insight into high-level corporate governance and business management matters which the Board considers on a regular basis. Back to top


Scott W. Drake

Mr. Drake has served as one of our directors since September 2013 and as Chairman of the Board since May 2018. Mr. Drake currently serves as the President and Chief Executive Officer of ViewRay, a publicly-held medical device company with global operations in radiation therapy and imaging technologies. Mr. Drake was most recently the President and Chief Executive Officer of Spectranetics Corporation from 2011 to 2017. Spectranetics, acquired by Philips in August of 2017, developed, manufactured and distributed single-use medical devices used in minimally invasive procedures within the cardiovascular system. Prior to joining Spectranetics, Mr. Drake served as Senior Vice President, Operations of DaVita, Inc., a leading U.S. provider of kidney care and dialysis. Previously, Mr. Drake spent 17 years in several positions within numerous healthcare business units at Covidien. From 2006 to 2009, he was President of Covidien’s Respiratory and Monitoring Solutions Global Business Unit, a $1.5 billion business with 8,000 employees. He has also served on the Board of Directors for The Zayo Group Holdings, Inc., since November 2018. Mr. Drake is the Chairperson of the AdvaMed Radiation Therapy Sector and a board member for the Medical Device Manufacturers Association (MDMA). Mr. Drake holds a B.S. in Business Administration from Miami University of Ohio. Mr. Drake’s significant leadership experience in the medical device industry provides him insight into the high-level corporate governance, executive compensation, regulatory (including FDA) and business management matters that the Company and the Board consider on a regular basis and gives him skills which the Board considers as valuable for evaluating and improving the Company’s competitive position and serving as Chairman of the Board of Directors. Back to top


Daniel P. Florin

Daniel P. Florin. Mr. Florin has served as one of our directors since December 2019. Mr. Florin most recently served as Executive Vice President at Zimmer Biomet Holdings, a publicly-held global leader in musculoskeletal healthcare until March 2020. He was appointed to his position in July 2019 upon announcing his intention to retire from the company. Previously he served as Executive Vice President and Chief Financial Officer of the company from June 2015 to July 2019. In addition, he served as Interim Chief Executive Officer of the company from July 2017 to December 2017. Prior to working at Zimmer Biomet, Mr. Florin was Chief Financial Officer for Biomet, Inc. until the company merged with Zimmer, Inc. and became Zimmer Biomet Holdings. Prior to working at Biomet, he held various roles at Boston Scientific, Inc., CR Bard, Inc. and Deloitte & Touche, LLP. Mr. Florin has served on the Board of Directors of Pulmonx since January 2020. Mr. Florin received an undergraduate degree from the University of Notre Dame and earned his M.B.A. from Boston University Executive MBA program.
Mr. Florin’s knowledge of the healthcare industry, proficiency in evaluating mergers and acquisitions, and significant experience as a chief financial officer and independent public accountant provides valuable skills to the Board. Mr. Florin qualifies as an “audit committee financial expert” under SEC rules. Back to top


Regina E. Groves

Ms. Groves has served as one of our directors since March 2017. Ms. Groves was most recently the Chief Executive Officer at REVA Medical, Inc. from September of 2015 to March 2019. Prior to joining REVA Medical, Ms. Groves served as Vice President and General Manager of the AF Solutions, Cardiac Rhythm and Heart Failure Division of Medtronic, a leading global medical technology company. In this position, she successfully developed and executed strategies to re-enter the catheter-based Afib ablation market and achieved the goal to be market leader in paroxysmal, or intermittent, Afib ablation. The role also allowed her to successfully acquire and integrate companies, complete numerous clinical trials, and launch novel products in the United States and worldwide. Prior to this, she was the Vice President of Quality and Regulatory for Medtronic’s Cardiac Rhythm Disease Management (“CRDM”) business from 2006 to 2008 and before that was Vice President and General Manager for Patient Management CRDM at Medtronic from 2002 to 2006. Ms. Groves holds a B.S. in Pharmacy from the University of Florida and an M.B.A. from Harvard Graduate School of Business Administration. As a seasoned executive in the medical device industry, Ms. Groves has significant leadership experience managing growing businesses, achieving sustainable revenue growth, driving operational improvements and managing quality and regulatory (including FDA) matters which the Board considers as valuable skills for evaluating and improving the Company’s competitive position. Back to top


B. Kristine Johnson

Ms. Johnson has served as one of our directors since March 2017. Ms. Johnson is currently President of Affinity Capital Management, a venture capital firm that invests primarily in seed and early-stage health care companies in the United States, a position she has held since 2000. Prior to her role at Affinity, Johnson was employed for 17 years at Medtronic, serving most recently as senior vice president and chief administrative officer from 1998 to 1999. Her experience at Medtronic also includes service as President and General Manager of its vascular business and President and General Manager of its tachyarrhythmia management business, among other roles. In addition to her role at Affinity, Ms. Johnson currently serves on the Board of Directors of Piper Jaffray (NYSE: PJC) and Chair of the Investment Advisory Board of the University of Minnesota Foundation and on the boards of several private entities. Her previous public board experience includes service on the Board of Directors of Spectranetics Corporation, which was acquired by Philips, ADC Telecommunications, which was acquired by Tyco Electronics, and Pentair. Ms. Johnson received her B.A. from St. Olaf College. Ms. Johnson brings extensive knowledge of health care and medical technology industries to the Board as well as broad experience in finance and corporate governance. Back to top


Mark R. Lanning, CPA, CGMA

Mr. Lanning has served as one of our directors since February 2006. Mr. Lanning currently is a financial consultant and a principal with the Lanning CPA group. Most recently Mr. Lanning served as Vice President-Finance and Chief Financial Officer of Frisch’s Restaurants for over 5 years. Prior to joining Frisch’s, Mr. Lanning served as Vice President, Investor Relations and Treasurer of Hillenbrand, Inc., Hill-Rom, Inc. and Hillenbrand Industries, diversified leaders in the healthcare equipment, funeral services, and material handling industries. Prior to joining Hillenbrand in 1988, Mr. Lanning spent twelve years in various accounting positions with Ernst & Whinney (now EY). Mr. Lanning, a Certified Public Accountant and a Chartered Global Management Accountant, is presently a member of the American Institute of CPAs (AICPA). In addition, he is a past Chairman and Board member of the Indiana CPA Society and has served on the boards of several charitable and educational institutions over the years. Mr. Lanning received his B.S. in Accounting from Ball State University. As a certified public accountant, Mr. Lanning developed significant experience in preparing, auditing, analyzing and evaluating financial statements and dealt with broad and complex accounting issues comparable to those of the Company, which qualifies him as an “audit committee financial expert” under SEC rules. Back to top


Karen N. Prange

Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein (Nasdaq: HSIC) and a member of the Executive Committee. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she led the Urology and Pelvic Health business for Boston Scientific, Inc. (NYSE: BSX) and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company (NYSE: JNJ). In addition to general management roles, Ms. Prange has extensive experience in commercial and operational roles, including managing innovation pipelines and acquiring and integrating companies. Ms. Prange serves on the board of Cantel Medical and is a strategic advisor for Nuvo Group. Ms. Prange earned her B.S. in Business Administration with honors from the University of Florida and has completed executive education coursework at UCLA Anderson School of Business and Smith College. Back to top


Sven A. Wehrwein

Sven A. Wehrwein has served on our board of directors since November 2016. Mr. Wehrwein has been an independent financial consultant to emerging companies since 1999. During his more than 35 years in accounting and finance, Mr. Wehrwein has experience as an investment banker to emerging-growth companies, chief financial officer, and certified public accountant (inactive). Wehrwein currently serves on the boards of several companies, including Proto Labs, Inc. and SPS Commerce, Inc. In addition, he has served as a Director for a number of other medical device and high growth companies including tenures on the boards of Cogentix Medical, Inc., Compellent Technologies Inc., Synovis Life Technologies, Inc., and Vital Images. Mr. Wehrwein holds a B.S. in Business from Loyola University of Chicago and an M.S. in Management from the Sloan School, MIT. Mr. Wehrwein brings capabilities in financial understanding, strategic planning and auditing to the Board, given his experiences in investment banking and financial leadership positions. Mr. Wehrwein qualifies as an “audit committee financial expert” under SEC rules.  Back to top


Robert S. White

Mr. White has served as one of our directors since March 2013. Most recently, Mr. White served as President and Chief Operating Officer of Entellus Medical. Entellus Medical, which was acquired by Stryker Corporation in February 2018, was a publicly-traded company that delivered innovative, high quality, minimally invasive therapeutic solutions to healthcare providers and their patients who suffer from sinusitis. Prior to joining Entellus, Mr. White served as President and CEO of TYRX, a privately-held company acquired by Medtronic, Inc. TYRX commercialized innovative, implantable combination drug and device products focused on infection control. Prior to joining TYRX, Mr. White held several positions with Medtronic, Inc. Mr. White served as President of Medtronic Kyphon following its $3.9 billion acquisition of the spinal treatment business. During his time with Medtronic, Mr. White also served as President of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as Vice President of U.S. Sales and Global Marketing. Earlier in his career, Mr. White held positions with General Electric Company and Eli Lilly and Company, among others. Mr. White recently served on the Board of Directors of HyperBranch Medical Technology until it was acquired by Stryker Corporation in October 2018. Mr. White also served on the Board of Directors of Novadaq, a publicly-traded provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, until it was acquired by Stryker Corporation in June 2018. Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University. Mr. White’s significant knowledge of the medical device industry and experience in growing companies commercially uniquely benefit AtriCure and enhance its capacities in business development initiatives. Back to top